

Hashimoto encephalopathy (steroid-responsive encephalopathy associated with autoimmune thyroiditis)

Condition for which IVIg use is in exceptional circumstances only

Specific Conditions

- Hashimoto encephalopathy

Level of Evidence

Insufficient data (Category 4a)

Intravenous immunoglobulin (IVIg) is not supported as first-line treatment, because preferable alternative treatments are available.

IVIg may be considered in exceptional circumstances where there is progressive neurologic decline despite appropriate steroid therapy.

Refer to the current product information sheet for further information.

The aim should be to use the lowest dose possible that achieves the appropriate clinical outcome for each patient.

Bibliography

Jacob, S & Rajabally, YA 2005, 'Hashimoto's encephalopathy: steroid resistance and response to intravenous immunoglobulins', *Journal of Neurology, Neurosurgery and Psychiatry*, vol. 76, no. 3, pp. 455–6.

Generated on: 31 March 2019